Afya Limited, through its subsidiaries, operates as a medical education group in Brazil. The company provides educational products and services, including medical schools, medical residency preparatory courses, graduate courses, and other programs to lifelong medical learners enrolled across its distribution network, as well as to third-party medical schools. It offers health sciences courses, which comprise medicine, dentistry, nursing, radiology, psychology, pharmacy, physical education, physiotherapy, nutrition, and biomedicine; and degree programs and courses in other subjects and disciplines, including undergraduate and post graduate courses in business administration, accounting, law, civil engineering, industrial engineering, and pedagogy. In addition, the company provides distance learning residency preparatory courses; and develops and sells digital and printed medical content. As of December 31, 2020, it operated a network of 24 undergraduate and graduate medical school campuses consisted of 19 operating units and five approved units. The company was founded in 1999 and is headquartered in Nova Lima, Brazil.
IPO Year: 2019
Exchange: NASDAQ
Website: afya.com.br
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/8/2025 | $24.50 | Neutral → Overweight | Analyst |
| 9/8/2025 | $19.00 | Neutral → Buy | UBS |
| 8/6/2025 | $17.50 | Underweight → Overweight | Morgan Stanley |
| 7/29/2025 | $14.00 | Sell → Neutral | Citigroup |
| 3/11/2025 | $19.00 → $17.00 | Equal-Weight → Underweight | Morgan Stanley |
| 1/31/2025 | $18.00 → $15.00 | Neutral → Sell | Citigroup |
| 12/3/2024 | $16.00 | Sell | Goldman |
| 8/30/2024 | $19.50 | Neutral | UBS |
| 1/29/2024 | $23.00 | Neutral | Citigroup |
| 1/22/2024 | $20.50 → $23.00 | Overweight → Equal-Weight | Morgan Stanley |
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Analyst upgraded Afya from Neutral to Overweight and set a new price target of $24.50
UBS upgraded Afya from Neutral to Buy and set a new price target of $19.00
Morgan Stanley upgraded Afya from Underweight to Overweight and set a new price target of $17.50
Citigroup upgraded Afya from Sell to Neutral and set a new price target of $14.00
Morgan Stanley downgraded Afya from Equal-Weight to Underweight and set a new price target of $17.00 from $19.00 previously
Citigroup downgraded Afya from Neutral to Sell and set a new price target of $15.00 from $18.00 previously
Goldman initiated coverage of Afya with a rating of Sell and set a new price target of $16.00
UBS initiated coverage of Afya with a rating of Neutral and set a new price target of $19.50
Citigroup initiated coverage of Afya with a rating of Neutral and set a new price target of $23.00
Morgan Stanley downgraded Afya from Overweight to Equal-Weight and set a new price target of $23.00 from $20.50 previously
S-8 - Afya Ltd (0001771007) (Filer)
6-K - Afya Ltd (0001771007) (Filer)
6-K - Afya Ltd (0001771007) (Filer)
6-K - Afya Ltd (0001771007) (Filer)
6-K - Afya Ltd (0001771007) (Filer)
6-K - Afya Ltd (0001771007) (Filer)
6-K - Afya Ltd (0001771007) (Filer)
6-K - Afya Ltd (0001771007) (Filer)
6-K - Afya Ltd (0001771007) (Filer)
6-K - Afya Ltd (0001771007) (Filer)
Fastest customizable press release news feed in the world
Impressive Adjusted EBITDA Margin Expansion and Cash Generation Full Year 2025 Guidance Reaffirmed Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, reported today its financial and operating results for the three and nine-month period, which ended September 30, 2025 (third quarter 2025). Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). Third Quarter 2025 Highlights 3Q25 Revenue increased 10.4% YoY to R$928.5 million. Revenue excluding acquisitions increased 10.1%, reaching R$926.2 million.
Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, today announced that the Secretary of Regulation and Supervision of Higher Education of the Ministry of Education ("MEC") authorized the increase of 100 medical seats of ITPAC Porto Nacional – Instituto Tocantinense Presidente Antonio Carlos Porto S.A. (AFYA Faculdade de Ciências Médicas Bragança), in the city of Bragança, located in the state of Pará. With the authorization, Afya reaches 150 medical seats on this campus, and 3,753 total approved seats. This significant presence underscores our commitment to providing quality medical educ
Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, announced today that it has entered into a Share Repurchase Agreement with SBLA Holdco LLC, an affiliate of Softbank, to repurchase all 150,000 Series A Perpetual Convertible Preferred Shares of a nominal or par value of US$0.00005 each in the capital of the Company (the "Series A Preferred Shares") for an aggregate purchase price of R$831.6 million. The transaction is expected to close on November 3, 2025. On April 26, 2021, the Company issued and sold 150,000 Series A Preferred Shares, equivalent to US$150.0 million in Reais, to Softba
Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, announced today that its wholly owned subsidiary Afya Participações S.A. ("Afya Brazil"), has approved today the first issuance of book-entry commercial notes, in two series, for private placement, (the "Commercial Notes"), to be sold to Opea Securitizadora S.A. ("Opea"), a Brazilian securitization corporation pursuant to Section 45 of Brazilian Law No. 14,195/2021, as amended. Opea will issue a debenture backed by the Commercial Notes on the same terms and conditions. The aggregate principal amount of the Commercial Notes is R$1,500.0 m
Impressive Adjusted EBITDA Margin Expansion and Cash Generation Full Year 2025 Guidance Reaffirmed Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, reported today its financial and operating results for the three and six-month period, which ended June 30, 2025 (second quarter 2025). Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). Second-Quarter 2025 Highlights 2Q25 Revenue increased 13.5% YoY to R$919.4 million. Revenue excluding acquisitions increased 8.5%, reaching R$879.0 million. 2
Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, announced today, its Board of Directors has approved a new share repurchase program. Under the share repurchase program, Afya may repurchase up to 4,000,000 of its outstanding Class A common shares, in the open market, based on prevailing market prices, or in privately negotiated transactions, beginning from August 15, 2025 until the earlier of the completion of the repurchase or December 31, 2026, depending upon market conditions. The share purchases may be made from time to time through open market transactions and are subject to marke
Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, announces the release of its 2024 Sustainability Report. The document, which presents Afya's trajectory throughout 2024, follows the Global Reporting Initiative (GRI) standards and is aligned with the Sustainable Development Goals (SDGs). It also reports specific indicators from the Sustainability Accounting Standards Board (SASB) and elements of the International Integrated Reporting Council (IIRC). The sustainability report contains some of the results of the fifth Greenhouse Gas (GHG) Emissions Inventory. Both of which have undergone
Afya Limited, or "Afya" (NASDAQ:AFYA) announced today that the resolutions set out in its Notice of Annual General Meeting dated June 9, 2025 was duly passed at its Annual General Meeting held today: (1) the approval and ratification of Afya's financial statements as of and for the fiscal year ended December 31, 2024; (2) the re-appointment of João Paulo Seibel de Faria as an independent director of the Company with immediate effect to hold office for a two year term; (3) the re-appointment of Vanessa Claro Lopes as an independent director of the Company with immediate effect to hold office for a two year term; (4) the re-appointment of Miguel Filisbino Pereira de Paula as an independent di
Notice is hereby given that an Annual General Meeting of the Company (the "AGM") will be held at the offices of Afya Participações S.A., Alameda Oscar Niemeyer, No. 119, 15th Floor, Vila da Serra, Nova Lima, Minas Gerais, Brazil, Zip Code: 34.006-056, and virtually by accessing the following link https://web.lumiconnect.com/283874046 (password: afya2025), on the 24th day of June 2025 at 10:00 a.m. BRT, for the purpose of considering and, if thought fit, passing and approving the following resolutions: "As an ordinary resolution, that the Company's financial statements and the auditor's report for the fiscal year ended December 31, 2024 be approved and ratified." "As an ordinary resolu
Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, announced today that its board of directors (the "Board"), following the recommendation of the Board's audit committee, recently approved the engagement of KPMG Auditores Independentes Ltda. ("KPMG") to provide independent auditing services for the Company, replacing Ernst & Young Auditores Independentes S/S Ltda., as its independent registered public accounting firm. KPMG will commence its activities with the review of our quarterly information for the second quarter of 2025. About Afya Limited (NASDAQ:AFYA, B3: A2FY34)) Afya is a l
Live Leadership Updates
Afya Limited, or "Afya" (NASDAQ:AFYA) announced today that the resolutions set out in its Notice of Annual General Meeting dated June 9, 2025 was duly passed at its Annual General Meeting held today: (1) the approval and ratification of Afya's financial statements as of and for the fiscal year ended December 31, 2024; (2) the re-appointment of João Paulo Seibel de Faria as an independent director of the Company with immediate effect to hold office for a two year term; (3) the re-appointment of Vanessa Claro Lopes as an independent director of the Company with immediate effect to hold office for a two year term; (4) the re-appointment of Miguel Filisbino Pereira de Paula as an independent di
NOVA LIMA, Brazil and MINAS GERAIS, Brazil, Jan. 15, 2021 (GLOBE NEWSWIRE) -- Afya Limited, or Afya (Nasdaq: AFYA), today announces that its clinical decision software, WhiteBook, an app created by PEBMED, was ranked as one of the 10 Top Apps in Brazil by consumer spend in 2020 for the fifth year in a row. App Annie conducted the study, a website specialized in app analytics and app market data that combined data from iOS and Google Play that evaluates more than 8 million mobile app per year. In the top ten WhiteBook was among great apps such as Tinder, YouTube, Netflix, TikTok and others. Whitebook is a mobile and web application software that helps doctors and medical students to make
Live finance-specific insights
Impressive Adjusted EBITDA Margin Expansion and Cash Generation Full Year 2025 Guidance Reaffirmed Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, reported today its financial and operating results for the three and nine-month period, which ended September 30, 2025 (third quarter 2025). Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). Third Quarter 2025 Highlights 3Q25 Revenue increased 10.4% YoY to R$928.5 million. Revenue excluding acquisitions increased 10.1%, reaching R$926.2 million.
Impressive Adjusted EBITDA Margin Expansion and Cash Generation Full Year 2025 Guidance Reaffirmed Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, reported today its financial and operating results for the three and six-month period, which ended June 30, 2025 (second quarter 2025). Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). Second-Quarter 2025 Highlights 2Q25 Revenue increased 13.5% YoY to R$919.4 million. Revenue excluding acquisitions increased 8.5%, reaching R$879.0 million. 2
Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, announced today, its Board of Directors has approved a new share repurchase program. Under the share repurchase program, Afya may repurchase up to 4,000,000 of its outstanding Class A common shares, in the open market, based on prevailing market prices, or in privately negotiated transactions, beginning from August 15, 2025 until the earlier of the completion of the repurchase or December 31, 2026, depending upon market conditions. The share purchases may be made from time to time through open market transactions and are subject to marke
Impressive Adjusted EBITDA Margin Expansion and Cash Generation Full Year 2025 Guidance Reaffirmed Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, reported today its financial and operating results for the three-month period ended March 31, 2025 (first quarter 2025). Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). First Quarter 2025 Highlights 1Q25 Net Revenue increased 16.4% YoY to R$936.4 million. Net Revenue excluding acquisitions increased 10.9%, reaching R$891.5 million. 1Q25 Adjusted
Impressive Adjusted EBITDA Margin Expansion Expressive Cash Generation First Dividend Announcement Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, reported today its financial and operating results for the fourth quarter and full-year period ended December 31, 2024. Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). Fourth Quarter 2024 Highlights 4Q24 Net Revenue increased 16.3% YoY to R$849.0 million. Net Revenue excluding acquisitions increased 12.0%, reaching R$817.8 million. 4Q24 Adjust
Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), Brazil's leading medical education group and provider of medical practice solutions, announced that its board of directors (the "Board") approved its first distribution of a cash dividend. On March 12, 2025, Afya's Board declared a cash dividend of R$129.8 million, representing 20% of the Company's consolidated net income of R$648.9 million for the year ended December 31, 2024. This amounts to a dividend per share (DPS) of R$1.348923, payable in U.S. dollars on April 4, 2025, to shareholders of record as of the close of business on March 26, 2025. The payment will be made at the exchange rate (PTAX) published on March 13, 2
Impressive Adjusted EBITDA Margin Expansion Robust EPS Expansion Expressive Cash Generation Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, reported today financial and operating results for the three and nine-month periods ended September 30, 2024 (third quarter 2024). Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). Third Quarter 2024 Highlights 3Q24 Net Revenue increased 16.3% YoY to R$841.2 million. Net Revenue excluding acquisitions grew 11.8%, reaching R$808.8 million. 3Q24 Ad
Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, announced today that it will report third-quarter and nine months 2024 financial results for the period ended September 30th, 2024, following the close of the market on Wednesday, November 13th, 2024 and will host a corresponding conference call and webcast at 05:00 pm EST. A live and archived webcast of the call will be available on the Investor Relations section of the Company's website at: https://ir.afya.com.br/financials/quarterly-earnings/ To participate in Afya's Third Quarter and Nine Months 2024 conference call, please follow
Solid Organic Growth Impressive Adjusted EBITDA Margin Expansion Robust EPS Expansion Afya Limited (NASDAQ:AFYA, B3: A2FY34))) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, reported today financial and operating results for the three and six-month period, which ended on June 30, 2024 (second quarter 2024). Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). Second Quarter 2024 Highlights 2Q24 Net Revenue increased 13.7% YoY to R$809.9 million. 2Q24 Adjusted EBITDA increased 28.2% YoY reaching R$343.8 million, with an Adjus
Solid Organic Growth Impressive Adjusted EBITDA Margin Expansion Robust EPS Expansion Afya Limited (NASDAQ:AFYA, B3: A2FY34))) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, reported today financial and operating results for the three-month period ended March 31, 2024 (first quarter 2024). Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). First Quarter 2024 Highlights 1Q24 Net Revenue increased 13.3% YoY to R$804.2 million. 1Q24 Adjusted EBITDA increased 20.5% YoY reaching R$397.9 million, with an Adjusted EBITDA Margin of
This live feed shows all institutional transactions in real time.
SC 13G/A - Afya Ltd (0001771007) (Subject)
SC 13G/A - Afya Ltd (0001771007) (Subject)
SC 13G/A - Afya Ltd (0001771007) (Subject)
SC 13D/A - Afya Ltd (0001771007) (Subject)
SC 13G/A - Afya Ltd (0001771007) (Subject)
SC 13G/A - Afya Ltd (0001771007) (Subject)
SC 13D/A - Afya Ltd (0001771007) (Subject)
SC 13D/A - Afya Ltd (0001771007) (Subject)
SC 13D/A - Afya Ltd (0001771007) (Subject)
SC 13D/A - Afya Ltd (0001771007) (Subject)